Eli Lilly (NYSE:LLY | LLY Price Prediction) is the stock everyone wants to own right now, a $1.02 trillion obesity juggernaut that has ripped 20.9% higher in a single month on the…
Pfizer (NYSE:PFE | PFE Price Prediction) is in the middle of its biggest reinvention in a generation, leaning on the Seagen oncology platform and the freshly closed Metsera obesity assets to offset…
Alex Sirois At $25.60, Pfizer (NYSE:PFE | PFE Price Prediction) sits in Hold territory on Wall Street’s consensus. The headline 6.7% dividend yield is reason to pause rather than pounce. A payout that fat…
Alex Sirois Pre-Market Stock Futures: Futures are trading lower after the stock market tried to take a cue from Monday’s action, and things didn’t work out quite as well on Tuesday. Once again, the…
Pfizer (NYSE:PFE | PFE Price Prediction) trades at $25.62, pays a 6.7% dividend yield, and just posted five straight quarterly EPS beats before stumbling in Q1. Yet the stock is up only…
Earned income has a ceiling. Hours in a day, headcount budgets, layoff cycles, and corporate restructurings all cap how much a paycheck can deliver. Passive income flips that dynamic. A properly built…
Pacer US Cash Cows 100 ETF (NYSEARCA:COWZ) owns the 100 Russell 1000 names that generate the most free cash flow relative to market value. That pitch has worked. COWZ trades around $64…
Pfizer (NYSE:PFE | PFE Price Prediction) and Merck (NYSE:MRK) both just closed earnings chapters that frame the 2026 dividend debate clearly. Pfizer wrapped fiscal 2025 with a $0.66 adjusted EPS Q4 beat.…
Pfizer (NYSE:PFE | PFE Price Prediction) is one of those names where the headline narrative (COVID hangover, patent cliff) keeps overshadowing what is actually a defensive cash machine trading at a single-digit…
Vandita Jadeja The smart money on Pfizer (NYSE: PFE | PFE Price Prediction) is sending a quieter signal than the financial press typically rewards: institutional analysts are constructive, insiders are not transacting in size…
Trey Thoelcke Polymarket traders are watching one biotech more closely than any other for an acquisition. Viking Therapeutics (NASDAQ: VKTX | VKTX Price Prediction) carries a 38.5% implied probability of being acquired before 2027,…
iShares Select Dividend ETF (NASDAQ:DVY) is one of the older income-focused funds on the market. The question for owners is simple: can the income stream hold up? DVY pays variable quarterly distributions…
With markets at elevated multiples in May 2026, low share prices can mislead investors into thinking quality is out of reach. Stocks trading below $30 with strong balance sheets offer income, deleveraging…
BridgeBio Pharma (NASDAQ:BBIO | BBIO Price Prediction) received a Neutral initiation from Citi Neutral on Tuesday, reflecting a measured stance on the company’s transthyretin amyloid cardiomyopathy (ATTR-CM) franchise. The call contrasts with…
With short-term rates still elevated, tariff uncertainty churning through earnings models, and credit spreads widening at the margins, balance sheet quality has quietly become the most underrated factor in equity selection. Stocks…
